Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015.
about
Hematopoietic stem cell transplantation for multiple sclerosis: is it a clinical reality?Reappraising the timing of transplant for indolent non-Hodgkin lymphomas.A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantationUnmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.Analysis of Factors that Influence Hematopoietic Recovery in Autologous Transplanted Patients with Hematopoietic Stem Cells from Peripheral BloodHaematopoietic stem cell transplantation for autoimmune diseases.RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMTHematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey.Immunomodulation Induced by Stem Cell Mobilization and Harvesting in Healthy Donors: Increased Systemic Osteopontin Levels after Treatment with Granulocyte Colony-Stimulating Factor.Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis.Hypomethylating agents after allogeneic blood stem cell transplantation.Evaluation of Quality of Life and Care Needs of Turkish Patients Undergoing Hematopoietic Stem Cell Transplantation.Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.The Rome Transplant Network model compared to the Italian Bone Marrow Donor Registry activity for unrelated donor search process and transplant efficiency for hematologic malignancy.JACIE accreditation for blood and marrow transplantation: past, present and future directions of an international model for healthcare quality improvement.Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?Alloreactivity: the Janus-face of hematopoietic stem cell transplantation.Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT).New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?Peripheral blood stem cells collection on spectra optia apheresis system using the continuous mononuclear cell collection protocol: A single center report of 39 procedures.Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients.Haplo-identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study.Good Outcome for Very High Risk Adult B-cell Acute Lymphoblastic Leukaemia Carrying Genetic Abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if Promptly Submitted to Allogeneic Transplantation, after Obtaining a Good Molecular Remission.Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis.Impact of the initial fitness level on the effects of a structured exercise therapy during pediatric stem cell transplantation.Lessons learnt from a process evaluation of an exercise intervention in patients treated with autologous stem cell transplantation.Safety of hematopoietic cell infusion in children with malignant and non-malignant diseases.Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma.Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation.Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow TransplantationHaploidentical hematopoietic stem cell transplantation with myeloablative conditioning regimen could serve as an optional salvage therapy for younger patients with refractory or relapsed aggressive non-Hodgkin lymphoma.Hematopoietic stem cell transplantation for T-cell large granular lymphocyte leukemia: a retrospective study of the European Society for Blood and Marrow Transplantation.[Allogeneic stem cell transplantation : An option for autoimmune diseases?]Patients' Main Concerns About Having a Sibling Stem Cell Donor - A Grounded Theory Study.Hematopoietic stem cell transplantation and quality of life during the first year of treatmentHematopoietic stem cell transplantation for Crohn's disease: Gaps, doubts and perspectivesToll-Like Receptor Stimulation by MicroRNAs in Acute Graft-vs.-Host Disease
P2860
Q28071992-4C1C0C85-4CBB-40EA-8C0D-75D39D1F8DC3Q30248407-19EC4E67-F053-402F-A341-7000E4B6F34BQ33573529-D9D81C59-134E-478E-80D2-F424855AC664Q33742940-F445DCEF-A187-4E5A-8A61-772BC899D356Q33889604-D7020EBA-8F20-4348-8B9A-6D29E24CFD42Q34551863-7095E52F-3DF2-4BDD-97E7-02E40C689131Q36036605-3B6C8491-A563-49C8-AE0E-CC43B44442ECQ36957809-C19C40A3-1D9D-4A0A-A071-2D76B3D1D6E0Q37134694-EDC3D908-D4AC-42A2-AFD4-5B80DA1057B6Q37388718-42DB8EFC-7430-4CF8-842C-037FE7DBD107Q37531039-7ADFF41D-DC13-4498-A705-2A7281BC224FQ37571703-D78448F2-6062-4186-8A68-C034BCA98B51Q37618811-CD08C27B-68B0-4ABA-9950-50DD73960B98Q37624593-069F9907-7566-4DE3-8590-78B5628AA141Q38728327-159C2442-24DA-49CF-AA91-3890B53265FCQ38739178-51677993-19C4-4EEF-93E1-B83B5635C761Q38860997-3D446393-CDB8-44FC-9B67-4A2AB1505BD8Q38922235-D7ECB0AD-5C82-47BB-83C1-5BF441F80F19Q39209783-558A25C9-AE63-4DC7-A780-D9BEE16B9CD2Q39307476-D495A90B-9A45-4C2A-A415-FA165B76DE9FQ39575941-A71BC338-F62E-489F-9FC9-F8B7DA49652BQ40081439-36DF5A85-A482-4AE5-8624-FBD4C02D5142Q40678281-8A86E3EE-F6CC-424A-A20D-92C022382EEFQ41479021-000EDFD9-5121-48CA-B7EF-8845F473A912Q47114304-D681855C-75F2-4E8C-ADFF-98935D186321Q47549329-99BCCA0A-D74D-435C-97EF-418D0CF0A810Q47901449-A37B04DA-EC0E-4BD6-852A-6FF8F25EFE8EQ48169085-649A2D0D-CBFF-466D-9232-94C35B749EF0Q48328423-FF0B95C5-E519-4672-AB35-58A0BA56613EQ49976405-6AB292BF-F45B-4E39-9404-E274109AEF19Q50912716-DC26BA06-A2CB-414E-AFF1-6501465B77C4Q50994207-5C1056B9-7685-4295-BC1C-C4CD3AF923CBQ52770387-0D82AB84-DC68-4220-9D63-6784008AC981Q52910441-C9154249-8F4C-4980-A80F-0E6BBB2035E5Q53923462-56FBAA87-DA36-4434-AB3A-95A1D7ACAF10Q55153801-8CA2624F-BD86-4CF0-B114-793E37119883Q58117403-6CBFDFB5-325B-4A6F-9780-EEBCE16D8AAEQ58551592-19975D40-6069-44D3-BD4C-4A9B7D093DECQ59130037-564D3C57-2E70-42DB-ABCD-3D86FB44682D
P2860
Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Indications for allo- and auto ...... rent practice in Europe, 2015.
@en
type
label
Indications for allo- and auto ...... rent practice in Europe, 2015.
@en
prefLabel
Indications for allo- and auto ...... rent practice in Europe, 2015.
@en
P2093
P2860
P50
P356
P1476
Indications for allo- and auto ...... rrent practice in Europe, 2015
@en
P2093
D Farge-Bancel
J H F Falkenburg
P2860
P2888
P304
P356
10.1038/BMT.2015.6
P407
P577
2015-03-23T00:00:00Z
P5875
P6179
1015112663